MeSH D058387 - candidemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Micafungin | Micafungin | 2021-07-30 | |||
| Mylan | Caspofungin | Caspofungin | 2017-09-29 | |||
| Cipla | Caspofungin | Caspofungin | 2018-07-12 | |||
| Merck Sharp & Dohme | Caspofungin | Cancidas | 2001-01-26 | $174 M | Y2022 | |
| Caspofungin | Cancidas (previously Caspofungin MSD) | 2001-10-23 | ||||
| Pfizer | Anidulafungin | Ecalta | 2007-09-20 | |||
| Zydus Therapeutics | Micafungin | Micafungin | 2022-10-24 | |||
| Apotex | Micafungin | Micafungin | 2020-11-05 | |||
| Endo | Micafungin | Micafungin | 2021-06-16 | |||
| Accord Healthcare | Caspofungin | Caspofungin Accord | 2016-02-11 | |||
| Astellas Pharma | Micafungin | Mycamine | 2005-03-16 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
100%6/6
Phase 3
47%7/15
Approved: 3Overall Success rate: 47%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use